Tech Company Financing Transactions

ImmunOs Therapeutics Funding Round

GIMV, Lightspeed Venture Partners and Samsara BioCapital participated in a $74 million Series B funding round for ImmunOs Therapeutics. The round was announced on 6/7/2022.

Transaction Overview

Company Name
ImmunOs Therapeutics
Announced On
6/7/2022
Transaction Type
Venture Equity
Amount
$74,000,000
Round
Series B
Investors

GIMV (Lead Investor) (Andreas Jurgeit)

Lightspeed Venture Partners (Lead Investor) (Shelley Chu)

Samsara BioCapital (Lead Investor) (Marcos Milla)

BioMed Ventures

Fiscus Ventures

GL Ventures

Mission BioCapital

Peak6

Pfizer Venture Investments

Schroder Adveq

Proceeds Purpose
The proceeds of the Series B will be used to fund the clinical development of ImmunOs' lead program, IOS-1002 (formerly iosH2), through Phase 2 clinical trials and to progress additional oncology and autoimmune disease programs within the Company´s HLA-based pipeline towards clinical development.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Wagistrasse 14
Schlieren, 8952
Switzerland
Phone
Undisclosed
Website
www.immunostherapeutics.com
Email Address
[email protected]
Overview
ImmunOs' approach is based on the identification of specific human leukocyte antigen (HLA) molecules that hyper-activate the immune system of patients with severe autoimmune disorders. The company has utilized this discovery to develop an HLA-based technology platform to generate a novel class of biologic therapeutics for the treatment of cancer and autoimmune disease.
Profile
ImmunOs Therapeutics LinkedIn Company Profile
Social Media
ImmunOs Therapeutics Company Twitter Account
Company News
ImmunOs Therapeutics News
Facebook
ImmunOs Therapeutics on Facebook
YouTube
ImmunOs Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Sean Smith
  Sean Smith LinkedIn Profile  Sean Smith Twitter Account  Sean Smith News  Sean Smith on Facebook
Chief Medical Officer
Christoph Renner
  Christoph Renner LinkedIn Profile  Christoph Renner Twitter Account  Christoph Renner News  Christoph Renner on Facebook
Chief Operating Officer
Jeffrey Abbey
  Jeffrey Abbey LinkedIn Profile  Jeffrey Abbey Twitter Account  Jeffrey Abbey News  Jeffrey Abbey on Facebook
Chief Scientific Officer
Osiris Belaunzaran
  Osiris Belaunzaran LinkedIn Profile  Osiris Belaunzaran Twitter Account  Osiris Belaunzaran News  Osiris Belaunzaran on Facebook
Vice President
Claudia Berger
  Claudia Berger LinkedIn Profile  Claudia Berger Twitter Account  Claudia Berger News  Claudia Berger on Facebook
VP - Bus. Development
Steve Coats
  Steve Coats LinkedIn Profile  Steve Coats Twitter Account  Steve Coats News  Steve Coats on Facebook
VP - Product Management
Lorenz Vogt
  Lorenz Vogt LinkedIn Profile  Lorenz Vogt Twitter Account  Lorenz Vogt News  Lorenz Vogt on Facebook

 

 

Browse more venture capital transactions:

Prev: 6/7/2022: Ethena venture capital transaction
Next: 6/7/2022: Calaxy venture capital transaction

 

Share this article

 

About Database of VC Transactions

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.